Roivant Sciences Ltd.
- Open
- 34.65
- Day high
- 35.34
- Day low
- 34.02
- Prev close
- 34.71
- Volume
- 39.1M
- Mkt cap
- $25.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.9
- P/S
- 3322.0
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$216.2M over the last 3 months (0 open-market buys, 29 sales)
- 🏛Institutions accumulating (13F)
Roivant Sciences Ltd. (ROIV) is a Healthcare company listed on NASDAQ. The stock is up 176% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 29 sales (SEC Form 4).
Roivant Sciences Ltd. (ROIV) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ROIV earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.30 | $-0.33 | -10.1% | $1M | -29.9% |
| May 20, 2026 | $-0.26 | $-0.36 | -38.5% | $3M | -26.2% |
| Feb 6, 2026 | $-0.27 | $-0.24 | +11.1% | $2M | -54.0% |
| May 29, 2025 | $-0.26 | $-0.22 | +16.5% | $8M | -86.0% |
| Aug 8, 2024 | $-0.24 | $-0.18 | +26.0% | $55M | +79.5% |
| May 30, 2024 | $-0.26 | $-0.23 | +13.0% | $29M | -6.7% |
| Feb 13, 2024 | $-0.27 | $-0.21 | +22.2% | $37M | +10.1% |
| Nov 13, 2023 | $-0.28 | $-0.26 | +7.1% | $37M | +23.2% |
| Aug 14, 2023 | $-0.26 | $-0.38 | -46.2% | $22M | -13.7% |
| Feb 13, 2023 | $-0.36 | $-0.49 | -36.1% | $17M | -6.1% |
| Nov 14, 2022 | $-0.41 | $-0.42 | -2.4% | $13M | +119.8% |
| Aug 15, 2022 | $-0.30 | $-0.48 | -60.0% | $4M | -39.8% |
ROIV insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 24, 2026 | Venker Ericofficer: President & Immunovant CEO | Tax | 13,909 | $36.84 |
| Aug 24, 2026 | Pulik Richardofficer: CFO | Tax | 5,749 | $36.84 |
| Aug 21, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Sell | 17,519 | $37.30 |
| Aug 21, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Sell | 144,756 | $36.48 |
| Aug 21, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Sell | 172,899 | $37.17 |
| Aug 21, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Option | 144,756 | $3.85 |
| Aug 21, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Option | 172,899 | $3.85 |
| Aug 21, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Option | 17,519 | $3.85 |
| Aug 18, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Option | 243,177 | $3.85 |
| Aug 18, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Option | 284,707 | $3.85 |
| Aug 18, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Sell | 284,707 | $36.25 |
| Aug 18, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Option | 31,801 | $3.85 |
| Aug 18, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Sell | 105,141 | $36.59 |
| Aug 18, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Sell | 243,177 | $36.23 |
| Aug 18, 2026 | Sukhatme Mayukhdirector, officer: President & CIO | Option | 136,942 | $3.85 |
Source: ROIV SEC Form 4 filings, latest Aug 24, 2026. For informational purposes only — not investment advice.
See the full ROIV insider & 13F page →Roivant Sciences Ltd. company profile
Overview
Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical and healthcare technology company founded in 2014 and headquartered in London, United Kingdom. The company went public in December 2020 and operates as a holding company that develops and commercializes innovative medicines across multiple therapeutic areas. Roivant has built a portfolio of subsidiary companies, each focused on specific drug development programs, and has successfully brought several products to market while maintaining a robust pipeline of clinical-stage assets targeting various diseases including autoimmune disorders, dermatological conditions, and rare diseases.
Business
Roivant Sciences operates in the biopharmaceutical industry, which involves the research, development, and commercialization of drugs derived from biological sources or using biotechnology methods. The company functions as a holding company with multiple subsidiary "Vants" - specialized biopharmaceutical companies that focus on specific therapeutic areas or drug development programs. The company's primary commercial product is VTAMA (tapinarof), a topical treatment for plaque psoriasis that was launched in 2022 and represents the first novel topical psoriasis treatment in decades. VTAMA works as an aryl hydrocarbon receptor (AhR) modulating agent, which helps reduce inflammation and normalize skin cell production. The drug is also being developed for atopic dermatitis (eczema), a related inflammatory skin condition. Roivant's clinical pipeline includes several key programs across different therapeutic areas: 1. Anti-FcRn Franchise (approximately 40-50% of pipeline value): This includes bateclimab and IMVT-1402, which are antibodies that target the neonatal Fc receptor (FcRn). These drugs work by reducing harmful antibodies in autoimmune diseases. The programs target conditions like myasthenia gravis (a neuromuscular disorder), Graves' disease (an autoimmune thyroid condition), and rheumatoid arthritis. 2. Brepocitinib Program (approximately 30-40% of pipeline value): This is a TYK2 inhibitor being developed for multiple inflammatory conditions including dermatomyositis (a rare muscle and skin disease), non-infectious uveitis (eye inflammation), and systemic lupus erythematosus. The drug works by blocking specific inflammatory pathways. 3. Other Programs (approximately 10-20% of pipeline value): Including mosliciguat for pulmonary hypertension, namilumab for sarcoidosis, and various early-stage programs targeting different therapeutic areas. The company also has a technology platform called VantAI that uses artificial intelligence and computational methods to accelerate drug discovery and development processes.
Revenue model
Roivant generates revenue through multiple business models reflecting its diversified biopharmaceutical portfolio. The primary revenue source is product sales from VTAMA, which generated approximately $75 million in net product revenue in fiscal 2024. The company sells VTAMA through traditional pharmaceutical distribution channels to pharmacies, with patients and insurance companies as the ultimate paying customers. Beyond direct product sales, Roivant employs a partnership and licensing model where it collaborates with larger pharmaceutical companies. For example, the company has partnerships with Pfizer for brepocitinib development and has licensing agreements that can generate milestone payments and royalties. The company also generates revenue through asset sales and divestitures, as demonstrated by the recent sale of DermaVant to Organon for $259 million in 2024. The company's profitability is significantly influenced by several key factors. Regulatory approval success represents the most critical factor, as FDA approvals can transform experimental drugs into revenue-generating assets worth hundreds of millions or billions of dollars. Clinical trial outcomes directly impact both development costs and future revenue potential, with positive results increasing asset values while negative results can eliminate entire programs. Pricing and market access dynamics heavily influence margins, particularly for rare disease treatments where the company can command premium pricing but must navigate complex insurance reimbursement processes. The company's focus on orphan diseases and conditions with limited treatment options typically allows for higher pricing power compared to more competitive therapeutic areas. Development and operational efficiency affects cash burn rates, with the company's decentralized "Vant" structure designed to optimize resource allocation across different programs. Partnership terms and deal structures can significantly impact economics, as seen in revenue-sharing arrangements and milestone payment structures that provide both upfront capital and future revenue streams.
Competitive moat
Roivant's competitive moat is moderate but growing, built primarily around its diversified portfolio of differentiated drug candidates and its unique organizational structure. The company's strongest moat elements include regulatory exclusivity for approved products like VTAMA, which provides market protection through patents and regulatory data exclusivity periods. For VTAMA specifically, the company benefits from being the first novel topical psoriasis treatment in decades, creating a significant first-mover advantage in a large, underserved market. The company's anti-FcRn franchise represents a potentially strong competitive position, as this mechanism of action addresses a fundamental pathway in autoimmune diseases with limited current treatment options. If successful, programs like bateclimab and IMVT-1402 could establish Roivant as a leader in this emerging therapeutic class, particularly given the company's focus on potentially best-in-class attributes such as improved dosing schedules and delivery methods. However, Roivant faces significant competitive threats and moat limitations. The biopharmaceutical industry is highly competitive, with large pharmaceutical companies possessing substantially greater resources for research, development, and commercialization. Companies like Pfizer, Roche, and Johnson & Johnson can outspend Roivant on clinical trials and marketing, potentially developing competing products or acquiring promising assets. Biosimilar competition represents a long-term threat, as successful biologics eventually face generic-like competition when patents expire. The company's dependence on clinical trial success creates inherent vulnerability, as negative trial results can quickly eliminate competitive advantages and asset values. Additionally, regulatory changes in drug pricing and approval processes could impact the company's ability to maintain premium pricing for its products. The company's moat is further challenged by the capital-intensive nature of drug development, requiring continuous funding for clinical trials and commercialization efforts. This creates ongoing dilution risk and dependence on capital markets, potentially weakening the company's competitive position during market downturns.
Risks & safety
Roivant maintains a strong financial safety profile with substantial cash reserves and minimal debt obligations, providing significant runway for continued operations and development activities. • Cash Position: $5.2 billion in cash and short-term investments as of December 2024, providing multiple years of operating runway at current burn rates • Debt Level: Minimal debt with debt-to-equity ratio of 0.019, indicating very low financial leverage and solvency risk • Liquidity: Current ratio of 37.9 and quick ratio of 37.9, demonstrating exceptional short-term liquidity position • Cash Burn: Operating cash flow of -$207 million in Q3 2024, indicating controlled burn rate relative to cash position • Valuation Metrics: - P/E ratio of 12.6 based on recent positive earnings - Price-to-book ratio of 1.65, reasonable for a growth-stage biotech - Enterprise value considerations complicated by negative EBITDA due to R&D investments • Other Considerations: Strong balance sheet provides flexibility for strategic acquisitions, partnership investments, and ability to weather clinical trial setbacks without immediate financing pressure. The company's recent share repurchase program and asset divestitures demonstrate active capital allocation management.
Recent development
Over the past few years, Roivant has executed several strategic pivots and developments that have transformed the company from a pure development-stage entity into a commercial-stage biopharmaceutical company. The most significant milestone was the successful launch of VTAMA in 2022, which became what management describes as the best-launching novel topical treatment in psoriasis history, generating $75 million in net revenue in fiscal 2024. The company has strategically focused its portfolio around its highest-value assets, particularly the anti-FcRn franchise. In 2024, Roivant designated IMVT-1402 as the lead program over bateclimab based on superior clinical data in Graves' disease, demonstrating the company's willingness to make data-driven decisions about resource allocation. The anti-FcRn programs have expanded beyond the original myasthenia gravis indication to include Graves' disease, rheumatoid arthritis, and other autoimmune conditions. Portfolio optimization has been a key theme, with the company divesting non-core assets like DermaVant to Organon for $259 million in 2024, while simultaneously investing in higher-potential programs. The company has also expanded the brepocitinib program into new indications including cutaneous sarcoidosis, targeting orphan inflammatory diseases where the company can achieve premium pricing. Roivant has implemented significant capital allocation initiatives, including a $1.5 billion share repurchase program and the elimination of debt obligations. The company has also been active in business development, continuously seeking to in-license new assets and expand its pipeline while maintaining financial discipline. The company has made strategic advances in clinical development efficiency, with multiple programs advancing toward Phase 3 studies and potential regulatory submissions. The VTAMA program is expanding beyond psoriasis into atopic dermatitis, representing a significant market expansion opportunity for the company's first commercial product.
ROIV company profile · for informational purposes only — not investment advice.
Track ROIV with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free